Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy

Journal of Nuclear Medicine

Volumn 44, Issue 10, 2003, Pages 1612-1617

  Terai, Hidenobu ^a   Shimizu, Masami ^a   Ino, Hidekazu ^a   Yamaguchi, Masato ^a   Uchiyama, Katsuharu ^a   Oe, Kotaro ^a   Nakajima, Kenichi ^a   Taki, Junichi ^a   Kawano, Masaya ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

123I metaiodobenzylguanidine; Hypertrophic cardiomyopathy; Pathophysiologic changes; Sympathetic nerve activity

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 3 IODOBENZYLGUANIDINE I 123; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG UPTAKE; HEART INNERVATION; HEART SCINTISCANNING; HEART VENTRICLE FUNCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MEDIASTINUM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; SYMPATHETIC TONE; ADRENERGIC SYSTEM; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; INNERVATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HEART VENTRICLES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYOCARDIUM; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0642372196     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review JAMA. 2002;287:1308-1320.
2. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998;81:1339-1344.
3. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population Circulation. 2000;102:858-864.
4. Eisenhofer G, Friberg P, Rundqvist B, et al Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676.
5. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-923.
6. Shimuzu M, Sugihara N, Kita Y, et al. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J. 1992;67:155-160.
7. 123I-meta-iodobenzylguanidine scintigraphy. Circulation. 1994;89:667-683.
8. 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J Nucl Med. 1999;40:1-5
9. Schafers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy Circ Res. 1998;82:57-62.
10. Li ST, Tack CJ, Fananapazir L, Goldstein DS. Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;35:1867-1873.
11. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43:1242-1244.
12. Shimizu M, Ino H, Okeie K, et al. Increased QT dispersion does not reflect the increased regional variation of cardiac sympathetic nervous activity in hypertrophic cardiomyopathy. Am Heart J. 2001;142:358-362.
13. Shimizu M, Ino H, Yamaguchi M, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med 2002;43:15-20
14. Germano G, Kiat H, Kavanagh PB, et al. Automatic quantification of ejection from gated myocardial perfusion. J Nucl Med. 1995;36:2138-2147.
15. 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329-1337.
16. 99mTc-tetrofosmin electrocardiographically gated SPECT. J Nucl Med 2001;42:1017-1024
17. Marian AJ, Roberts R The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
18. Kokado H, Shimizu M, Yoshio H, et al Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 2000;102:663-669.
19. Fujino N, Shimizu M, Ino H, et al A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. Am J Cardiol. 2002;89:29-33.
20. Shimizu M, Ino H, Okeie K, et al. Septal wall thinning and systolic dysfunction in patients with hypertrophic cardiomyopathy caused by a cardiac troponin I gene mutation. Am Heart J 2002;143:690-695
21. Horita Y, Shimizu M, Sugihara N, et al. An autopsy case of hypertrophic cardiomyopathy showing dilated cardiomyopathy like features by serial ventriculography. Jpn J Med. 1990;29:448-453.
22. Carnici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17:879-886.
23. 201Tl Nucl Med Commun. 1993;14:181-188.
24. Taki J, Nakajima K, Shimizu M, Tonami N, Hisada K Left ventricular functional reserve in nonobstructive hypertrophic cardiomyopathy: evaluation by continuous left ventricular function monitoring. J Nucl Med 1994;35:1937-1943
25. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75:1130-1139.
26. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101:2579-2585.
27. 123I-labelled methyl-branched fatty acid and sympathetic imaging in acute coronary syndrome Nucl Med Commun 1995;16:393-503.
28. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort JAMA. 1999;281:23-30.
29. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987;60:123-129.
30. Seiler C, Jenni R, Vassalli G, Turina M, Hess OM. Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy. Br Heart J. 1995;74:508-516.